Nexavar, owned by Bayer Hlthcare, is a medication with the active ingredient sorafenib tosylate. It was first authorised for market use on December 20, 2005. The drug comes in tablet form taken orally and is covered by three patents, with one already expired.
The last patent protecting Nexavar is set to expire on September 10, 2028. Upon this date, it will be possible for generic versions of Nexavar to be released on the market.
Nexavar is used for the treatment of various types of cancers including advanced renal cell carcinoma, locally recurrent or metastatic thyroid carcinoma refractory to radioactive iodine treatment, unresectable hepatocellular carcinoma, and differentiated thyroid carcinoma. Its active ingredient, sorafenib tosylate, plays a crucial role in its cancer-fighting properties.
Two patents protect Nexavar: US8877933 expiring on December 24, 2027, and US9737488 expiring on September 10, 2028. A third patent, US8618141, has already expired. Once the last patent expires, the door will open for Nexavar generics. Below are the details of the patent: